Company intelligence / Profile preview
Neuphoria Therapeutics Inc.
Burlington, Massachusetts, United Statesneuphoriatx.com ↗
- Ownership
- Public · NEUP
- Employees
- ~24
- Development stage
- Phase 2
01
Overview
Lead candidate BNC210 is in Phase 3 for social anxiety disorder and Phase 2b for PTSD. BNC101 has completed Phase 1 for cancer stem cells. BNC105 is in Phase 2 for refractory colorectal cancer and Phase 1 for chronic lymphocytic leukemia.
- Therapeutic areas
- OncologyPsychiatryNeurology
- Modalities
- Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Merck & Co., Inc.Carina Biotech
04
Financials
- Market cap
- $15M
- Total revenue
- $1.2M
- Enterprise value
- $-4.8M
Beyond the preview
Go deeper on Neuphoria Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuphoria Therapeutics Inc..